Portage Biotech presented preclinical data for PORT-7 (TT-4), a selective A2B adenosine receptor inhibitor, at the 2025 European Lung Cancer Congress. The data showed single-agent activity and significant tumor growth inhibition when combined with an anti-PD1 antibody in a murine mesothelioma model. This is reportedly the first demonstration of antitumor activity against mesothelioma using a selective A2B receptor inhibitor.
This preclinical success is crucial because mesothelioma is an aggressive cancer with limited effective treatment options. The demonstrated efficacy of PORT-7, both alone and in combination with existing immunotherapy, offers a potential new avenue for treating this challenging disease, addressing a critical unmet need. The increased immune cell infiltration observed in the tumors further strengthens the rationale for this approach, suggesting a robust immune response.
Portage Biotech is preparing to initiate a first-in-human clinical trial with PORT-7. Concurrently, they are advancing the dose escalation of PORT-6, an A2A adenosine receptor inhibitor, with plans to combine PORT-6 and PORT-7 in the ongoing ADPORT-601 trial. This combined approach aims to fully block adenosine-induced immunosuppression, a key mechanism by which tumors evade the immune system.
The initiation of human trials for PORT-7 and the planned combination trial of PORT-6 and PORT-7 represent significant milestones in the development of these novel immunotherapies. Positive clinical results could lead to a new standard of care for mesothelioma, potentially improving outcomes for patients facing this difficult-to-treat cancer. The combined blockade of A2A and A2B receptors represents a promising new strategy in immuno-oncology, potentially applicable to a broader range of solid tumors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
